Abstract: The hematopoietic toxicity of ethylene glycol monomethyl ether (EGME) and its metabolites, methoxy acetaldehyde (MALD) and methoxyacetic acid (MAA), was analyzed using human bone marrow cells from a lymphoma patient without bone marrow involvement and a human leukemia cell line, HL 60. After 24-hour incubation, the concentrations of 50 percent inhibition (IC 50 ) of human hematopoietic progenitor cells with MALD or MAA were 3 mM and 3.9 mM, respectively, and EGME (10 mM or more) did not show any cytotoxicity. IC 50 (after 48-hour exposure) of MALD and MAA on HL 60 cells were 2.45 mM and 5.6 mM, respectively, suggesting that both hematopoietic progenitor cells and HL60 have a similar sensitivity. DNA ladder formation, a characteristics of apoptosis, was observed in MALD-or MAA-treated HL60 cells, but not in EGME-treated samples. Caspase-3 enzyme activity, the effector of the apoptotic process, was greatly enhanced with MALD treatment. The inhibitor of caspase-3 repressed cell death induced with MALD as well as MAA.
Ethylene glycol monomethyl ether (EGME) is widely employed as an industrial solvent as well as diverse household products. The widespread production and use of EGME has resulted in many reports of human poisoning by accidental ingestion or occupational exposure.
Exposure of laboratory rodents to EGME has been found to produce a variety of toxicologic effects 1) . The toxicity reported for short-chain ethylene glycol ethers such as EGME or 2-ethoxyethanol (2EE) is dependent on the sequential metabolism of these compounds by alcohol and aldehyde dehydrogenase enzymes (mainly in the liver) with formation of the corresponding metabolites. In the case of EGME, methoxy acetoaldehyde (MALD) and methoxy acetic acid (MAA) are formed, and are eliminated predominantly in the urine 2) . In hematopoiesis, there have been a limited number of case reports 3) showing mild macrocytic anemia and leukopenia, and laboratory animals exposed with these metabolites showed bone marrow hypocellularity resulting in pancytopenia 4) . However, the data on human bone marrow cells remain insufficient, and the mechanism of their toxicity has not been studied extensively 5) . Here, we report the results of short-term culture of EGME and its metabolites on human hematopoietic progenitor cells Industrial Health 2002, 40, 371-374 as well as human leukemia cell lines. To determine the probable cause of the hematopoietic toxicity of these reagents, caspase 3 enzyme activity, which triggers apoptosis, was measured, and the effect of caspase 3 inhibitor was analyzed. EGME and MAA were purchased from Sigma (St. Louis, Mo, USA). MALD was synthesized by Dr. H. Sajiki (Gifu Pharmaceutical University, Gifu, Japan) according to a previously described method 6) . The final solution contained 18% MALD in 50% methanol. The cell permeable caspase 3 inhibitor, Z-DEVD-FMK was from Calbiochem (San Diego, CA, USA).
Human bone marrow cells were obtained from a patient with non Hodgkin's lymphoma after obtaining the informed consent. Low density mononuclear cells (1.5 × 10 5 /ml) were treated with various concentrations of EGME, MALD and MAA for 24 hours in RPMI 1640 medium with 10% fetal calf serum (FCS). After 24 hour incubation, a progenitor cell assay was performed basically as described previously 7) . The respective numbers of myeloid colony (CFU-GM) and erythroid colony (BFU-E) were counted under the inverted microscope.
A human leukemia cell line, HL60 was cultured in 10% FCS in RPMI 1640 medium. Cells (2 or 5 × 10 5 /ml) were treated with various doses of EGME, MALD and MAA. Viable cell number was measured sequentially. In some experiments, caspase 3 inhibitor was added 30 minutes before the addition of MALD or MAA. DNA ladder formation was analyzed as described before 8) . Caspase 3 enzyme activity was measured using caspase 3 8 and 9 colorimetric protein assay kit (Medical Biological Laboratory Inc, Nagoya, Japan) under the instruction of manufacturer's guide. Briefly, 150 µg of protein lysate in 50 µl of lysis buffer was mixed with 50 µl of 2X reaction buffer. Then, the respective substrate (DEVD-pNA substrate for caspase 3, IETD-pNA substrate for caspase 8, and LEHDpNA substrate for caspase 9, respectively) was added. After the incubation for 1-2 hours at 37°C, OD 405 nm was measured with a micro-titer plate reader. Fold increase of each caspase activity was determined by comparing the result with the level of the non-treated control. Figure 1 presents the result of progenitor cell colony formation of human bone marrow cells after one day exposure of each reagent in suspension culture. In this typical experiment, about 400 colonies (including both BFU-E and CFU-GM) were formed out of 1.5 × 10 5 bone marrow cells without drug treatment. EGME (2, 5 and 10 mM) were not inhibitory for human progenitor cells. However, MALD and, to a lesser extent, MAA, inhibited colony formation in a dose dependent manner. The concentration needed for 50% inhibition of the control (normal) hematopoietic progenitor cell number (IC 50 ) of MALD and MAA were 3 mM and 3.9 mM, respectively. Both erythroid progenitor and myeloid progenitor were inhibited similarly with MALD or MAA.
Because of the difficulty in obtaining sufficient human bone marrow samples repeatedly, HL60, a human leukemia cell line was analyzed for further experiments. Figure 2A shows the relationship between viable cell number and the concentration of each reagent. MALD and MAA but not EGME inhibited the growth and survival of HL60 cells, which is consistent with the data on normal human hematopoietic progenitor cells. IC 50 of MALD and MAA (two days' continuous exposure) were 2.45 and 5.60 mM, respectively. EGME did not show inhibition.
During the culture peroid, morphological changes such as chromatin condensation and cell shrinkage, which are unique to apoptosis, were observed (data not shown). DNA ladder formation was analyzed using HL60 cells treated with MALD. Figure 2B shows a typical experiment indicating the presence of 180 base pair ladder.
We analyzed the effect of MALD (as the representative of EGME related metabolites) on the caspase 3 enzyme activities of cells (Fig. 3A) . Caspase 3 activation was clearly observed in MALD-treated cells in a dose dependent fashion. However, Fig. 1 . Effects of EGME, MALD and MAA on normal human hematopoietic progenitor cells. Inhibitory effects of EGME, MALD and MAA were shown compared to untreated control. After 24-hour incubation with various concentrations of each reagent (mM), mononuclear bone marrow cells (1.5 × 10 5 cells/ ml) were plated in semi-solid medium in triplicates. After an appropriate time, colony numbers were counted as described in the Methods. The ordinate indicates the colony number/plate. Erythroid (BFU-E) and myeloid (CFU-GM) colony number are summed as the total colony number. To the total colony number, SD was added to each column.
we did not observe activation of both caspase 8 and caspase 9, which located upstream of caspase 3. Finally, we attempted a rescue experiment using caspase 3 inhibitor, Z-DEVD-FMK. We can observe the significant preservation of cell viability with this inhibitor, especially with MALD treatment of 4 or 6 mM (Fig. 3B) as well as MAA treatment (data not shown).
In the present study, we showed the cytotoxicity of MALD and MAA on human hematopoietic progenitor but not that of EGME. It is of note that the mM order of metabolites is necessary for a short-term exposure experiment to observe significant hematopoietic toxicity. It can thus be argued that the concentration used in this study were too high to have direct relevance to the toxic effects these compounds might have in vivo. However, more sensitive assay such as Annexin V staining might have detected subtle and earlier changes in apoptosis. In our experiment, the dose-response curve was found to shift towards lower concentrations with incubation times. Thus, one may presume that a lower concentration should be active in chronic exposure.
Concerning the myelotoxicity of EGME, Teheux noticed the necessity of re-evaluation of an earlier in vitro study 9) . However, the elucidation of the mechanism of its toxicity is nevertheless important for the understanding of these compounds' toxicity. Our results suggest that the order of cytotoxicity is the aldehyde form as the strongest, followed by the acetic acid form, and then the ether form. However, the present results do not explain the apparent differences of in vivo cytotoxicity between various ethylene glycol ethers. Further analysis is necessary to explain these differences.
Till now, there are no data showing a dose-response relationship between EGME-related metabolites and human hematopoietic progenitor cells. Our data revealed that human hematopoietic progenitor cells have a sensitivity to EGMErelated metabolites to that of the cell lines reported by Ruchaud et al. 5) . Our IC 50 value for each metabolite in human leukemia cell line, HL 60, confirmed his report.
Recently, apoptosis has been regarded as an important physiological as well as pathological mechanism of the determination of a cell's fate. Ku et al. 10) reported the induction of apoptosis in a thymus and testis in vivo experiment. In the present study, the DNA ladder of around 180 base pairs, which is the characteristic of typical apoptosis, was observed in MALD treated HL60 cells.
The caspases are a family of enzymes that are involved in the process of apoptosis. These enzymes are composed of two hierarchical structures, in which an apical caspase (e.g., caspase 8 or caspase 9) triggers the partial digestion and activation of the effector caspases that are the main player of the destruction of various cellular proteins. Strong activation of caspase 3, the main downstream caspase, was observed with MALD treatment in a dose dependent manner. Because cell permeable caspase 3 inhibitor repressed MALD-induced apoptosis, caspase 3 would seem to be involved with MALDinduced hematotoxicity, although the upstream caspases, 8 and 9 did not show their activation in our system (data not shown). The remaining possibilities are that (1) other caspases, such as caspase 1 or caspase 11 is activated or that (2) other signaling pathways such as MAP kinase are mainly involved. Further analysis for the upstream trigger is necessary. Taken together, our results determined the IC 50 of MALD and MAA upon human hematopoietic progenitor cells as well as HL60 cells, and showed caspase 3 induced apoptosis was the probable cause of the hematopoietic toxicity of MALD and MAA.
